Amylyx Pharmaceuticals (AMLX) Competitors

$14.58 +0.14 (+0.97%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$14.34 -0.24 (-1.64%)

As of 06:14 AM Eastern

AMLX vs. MIRM, SYRE, RYTM, PTGX, and BLTE

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Amylyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amylyx Pharmaceuticals include Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), Protagonist Therapeutics (PTGX), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 25 mentions for Mirum Pharmaceuticals and 16 mentions for Amylyx Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.36 beat Amylyx Pharmaceuticals' score of -0.06 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals presently has a consensus target price of $23.00, indicating a potential upside of 57.75%. Mirum Pharmaceuticals has a consensus target price of $136.42, indicating a potential upside of 24.97%. Given Amylyx Pharmaceuticals' higher probable upside, equities analysts plainly believe Amylyx Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Amylyx Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	18.55	-$144.74M	-$1.50	N/A
Mirum Pharmaceuticals	$521.31M	12.77	-$23.36M	-$13.61	N/A

Summary

Mirum Pharmaceuticals beats Amylyx Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Amylyx Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	18.55	-$144.74M	-$1.50	N/A
Spyre Therapeutics	$890K	7,445.80	-$155.20M	-$2.08	N/A

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 16 mentions for Amylyx Pharmaceuticals and 10 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.89 beat Amylyx Pharmaceuticals' score of -0.06 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, indicating that its share price is 212% more volatile than the broader market.

Amylyx Pharmaceuticals presently has a consensus target price of $23.00, indicating a potential upside of 57.75%. Spyre Therapeutics has a consensus target price of $90.25, indicating a potential upside of 18.27%. Given Amylyx Pharmaceuticals' higher possible upside, equities research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spyre Therapeutics' return on equity of -42.88% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Spyre Therapeutics	N/A	-42.88%	-27.76%

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spyre Therapeutics beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	18.55	-$144.74M	-$1.50	N/A
Rhythm Pharmaceuticals	$189.76M	33.85	-$196.54M	-$3.13	N/A

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 19 mentions for Rhythm Pharmaceuticals and 16 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of -0.06 beat Rhythm Pharmaceuticals' score of -0.18 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

Amylyx Pharmaceuticals presently has a consensus target price of $23.00, indicating a potential upside of 57.75%. Rhythm Pharmaceuticals has a consensus target price of $131.81, indicating a potential upside of 40.65%. Given Amylyx Pharmaceuticals' higher possible upside, equities research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Protagonist Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	18.55	-$144.74M	-$1.50	N/A
Protagonist Therapeutics	$46.02M	145.17	-$130.15M	-$1.81	N/A

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 16 mentions for Amylyx Pharmaceuticals and 15 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.10 beat Amylyx Pharmaceuticals' score of -0.06 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals presently has a consensus price target of $23.00, suggesting a potential upside of 57.75%. Protagonist Therapeutics has a consensus price target of $113.69, suggesting a potential upside of 9.45%. Given Amylyx Pharmaceuticals' higher possible upside, research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Amylyx Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Belite Bio?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Belite Bio. MarketBeat recorded 16 mentions for Amylyx Pharmaceuticals and 10 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.71 beat Amylyx Pharmaceuticals' score of -0.06 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	18.55	-$144.74M	-$1.50	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A

Amylyx Pharmaceuticals currently has a consensus price target of $23.00, indicating a potential upside of 57.75%. Belite Bio has a consensus price target of $202.33, indicating a potential upside of 31.80%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Amylyx Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, meaning that its stock price is 219% less volatile than the broader market.

Belite Bio's return on equity of -19.49% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Belite Bio	N/A	-19.49%	-19.05%

Summary

Amylyx Pharmaceuticals beats Belite Bio on 10 of the 15 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.61B	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-9.72	18.86	21.03	25.58
Price / Sales	18.55	289.31	552.98	78.84
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	5.93	4.35	9.82	6.66
Net Income	-$144.74M	$72.19M	$3.55B	$333.63M
7 Day Performance	-4.08%	-1.05%	-0.53%	-0.11%
1 Month Performance	-13.88%	-0.02%	1.20%	3.94%
1 Year Performance	235.17%	46.31%	41.23%	36.07%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	2.6461 of 5 stars	$14.58 +1.0%	$23.00 +57.8%	+224.7%	$1.61B	$87.37M	N/A	200	Trending News Earnings Report Analyst Revision
MIRM Mirum Pharmaceuticals	2.5226 of 5 stars	$106.17 -0.9%	$136.42 +28.5%	+141.1%	$6.53B	$521.31M	N/A	140	Analyst Revision
SYRE Spyre Therapeutics	2.4147 of 5 stars	$76.43 +1.9%	$89.08 +16.6%	+417.4%	$6.52B	$890K	N/A	73	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.4176 of 5 stars	$87.39 -7.2%	$131.81 +50.8%	+65.0%	$6.45B	$189.76M	N/A	140	Trending News Analyst Revision Gap Up
PTGX Protagonist Therapeutics	1.8044 of 5 stars	$103.50 +4.2%	$113.69 +9.8%	+134.7%	$6.39B	$46.02M	N/A	120	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. MIRM, SYRE, RYTM, PTGX, and BLTE

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. MIRM, SYRE, RYTM, PTGX, and BLTE

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Does the media favor AMLX or MIRM?

Do analysts recommend AMLX or MIRM?

Which has more risk & volatility, AMLX or MIRM?

Do insiders and institutionals believe in AMLX or MIRM?

Is AMLX or MIRM more profitable?

Which has stronger earnings and valuation, AMLX or MIRM?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Which has higher earnings & valuation, AMLX or SYRE?

Does the media refer more to AMLX or SYRE?

Which has more volatility and risk, AMLX or SYRE?

Do analysts recommend AMLX or SYRE?

Is AMLX or SYRE more profitable?

Do institutionals and insiders believe in AMLX or SYRE?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Which has higher earnings & valuation, AMLX or RYTM?

Does the media refer more to AMLX or RYTM?

Which has more volatility and risk, AMLX or RYTM?

Do analysts recommend AMLX or RYTM?

Is AMLX or RYTM more profitable?

Do institutionals and insiders believe in AMLX or RYTM?

Summary

How does Amylyx Pharmaceuticals compare to Protagonist Therapeutics?

Is AMLX or PTGX more profitable?

Do institutionals and insiders have more ownership in AMLX or PTGX?

Which has stronger valuation and earnings, AMLX or PTGX?

Does the media refer more to AMLX or PTGX?

Do analysts rate AMLX or PTGX?

Which has more volatility & risk, AMLX or PTGX?

Summary

How does Amylyx Pharmaceuticals compare to Belite Bio?

Do insiders & institutionals have more ownership in AMLX or BLTE?

Does the media favor AMLX or BLTE?

Which has better valuation and earnings, AMLX or BLTE?

Do analysts prefer AMLX or BLTE?

Which has more risk and volatility, AMLX or BLTE?

Is AMLX or BLTE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools